Introduction
Gap junctions are specialized channels that connect adjacent cells and enable metabolic and electrical co-ordination between them (Pitts and Simms, 1977; Bennet and Goodenough, 1978) . The major structural protein of gap junctions is connexin. There are many different kinds of connexins encoded by a multigene family dispersed on numerous chromosomes (Fishman et al., 1991) . Connexin 43 (Cx43) is one of the most widely expressed members of this gene family, and is found in numerous tissues such as the uterus, heart, lens epithelium, kidney, mammary gland, ovary, placenta and intestine (Beyer et al., 1987; Risek and Gilula, 1991; Lee et al., 1992; Li et al., 1993) . The onset of labour is preceded by a dramatic increase of gap junctions in uterine smooth muscle, the myometrium (Garfield et al., 1977; Miller et al., 1989; Hendrix et al., 1992; Chow and Lye, 1994) . This increase is believed to enable the development of co-ordinated and intense uterine contractions necessary for the delivery of the fetus, whereas its suppression before term is believed to aid uterine quiescence. Evidence to support this concept comes from many functional studies showing that propagation of electrical activity of the myometrium is increased significantly during labour when gap junctions/Cx43 protein concentrations are increased (Garfield et al., 1977 (Garfield et al., , 1988 Sims et al., 1982; Cole et al., 1985; Miller et al., 1989; Miyoshi et al., 1996) .
Cx43 mRNA and protein concentrations in the myometrium are low during pregnancy, but rise markedly at term, remain high throughout labour, then decline rapidly following delivery in rat (Risek et al., 1990; Hendrix et al., 1992; Tabb et al., 1992; Lye et al., 1993; Winterhager et al., 1993) , sheep (McNutt et al., 1994) and human (Garfield and Hayashi, 1981) . While the expression of Cx43 is up-regulated by oestrogens (Garfield et al., 1977; MacKenzie and Garfield, 1985) and down-regulated by progesterone (Garfield et al., 1977; MacKenzie and Garfield, 1985; Petrocelli and Lye, 1993; Zhao et al., 1996) the molecular events that regulate transcriptional activation remain unclear.
Rat (Yu et al., 1994) , mouse (Chen et al., 1995) , and human Cx43 promoters have been cloned and sequenced. In these promoters, extensive homology exists between -175 to ϩ143, relative to the start site of transcription (Chen et al., 1995) . Transient expression studies (DeLeon et al., 1994; Chen et al., 1995; Geimonen et al., 1996) indicated that this region is important for regulating Cx43 promoter activity. It is likely, therefore, that similar regulatory elements may be operational within this promoter region in these species.
In the mouse, genetic and biochemical studies have demonstrated both 'repressor' (-100 to -91) and 'activator' (-68 to -59) promoter elements (Chen et al., 1995) . These regions are Ͼ90% conserved in the human Cx43 promoter. Transient transfection experiments in human cardiac myocytes have revealed the presence of negative regulatory element(s) between -2400 and -360 and a positive element between -175 and -50 of Cx43 gene (DeLeon et al., 1994) . Transcription of the human Cx43 gene can be induced in primary human myometrial cell cultures after activation of protein kinase C by tetradecanoyl phorbol acetate (TPA) treatment . Human Cx43 promoter region from -697 to ϩ170 has been used in mutation analysis and transient expression studies to demonstrate that TPAinduced activation required a consensus Activator Protein 1 (AP1) site located between positions -44 to -36. The AP1 site is conserved between rodent and human promoters but distinct from the mouse 'activator' region (Chen et al., 1995) . In addition, these studies demonstrated that TPA induced a dramatic rise in the protein concentrations of both c-Jun and c-Fos, further supporting the notion that transcriptional activation occurred through the promoter proximal AP1 site. However, over-expression of c-Jun and or c-Fos in the absence of TPA treatment had no effect on promoter activity, suggesting that TPA functioned by increasing and activating c-Jun/c-Fos.
In this report, we used a combination of DNase I footprinting, electrophoresis mobility shift (EMSA) and transient transfection assays to begin a systematic study of the human Cx43 promoter. We confirm previous studies and extend them by showing that the Ap1 site functionally interacts with c-Jun. In addition, we demonstrate that the Cx43 promoter contains tandem Specificity Protein 1 (Sp1) binding sites and that the proximal site, which is encompassed within a promoter segment homologous to the mouse 'activator' element functionally activates transcription. Furthermore, we show that over-expression of c-Jun and Sp1 either alone or in combination up-regulates Cx43 transcription in untreated primary cells in culture. Thus, both Sp1 and c-Jun are capable of and necessary for positively regulating human myometrial Cx43 transcription.
Materials and methods

Cell culture
Approval for the use of human tissue was obtained from the University of Texas Medical Branch Committee on Research Involving Human subjects. To obtain human myometrial factors that bind the Cx43 promoter at term when the levels of Cx43 mRNA and gap junctions are high, nuclear extracts should be made from myometrium obtained from biopsies or Caesarean section at these times. The quantity of tissue obtained from biopsies is insufficient for making amounts of nuclear proteins needed for our experiments. Moreover, it is difficult to homogenize human myometrium to liberate intact nuclei without first freezing the tissue or using harsh disintegration procedures that also break the nuclei and freezing is not recommended for preparing factors active in transcription (M.G.Izban, personal communication). Crude nuclear extracts were prepared from primary cultures of human myometrial cells initiated and grown as follows: the tissue from Caesarian sections or biopsies (from patients, gestational age, 37-39 weeks and not in labour) was cleaned of blood vessels, fat and endometrium. It was washed several times in wash buffer, Hank's balanced salt solution (HBSS; Gibco Life Technologies, Grand Island, NY, USA), supplemented with 100 IU/ml penicillin G; 100 µg/ml streptomycin sulphate and 25 µg/ml amphotericin B as fungizone (Gibco); then minced and rinsed three times in the same buffer. It was then digested for~75 min at 37°C with three times its volume of dispersion solution (HBSS, containing 1 mmol/l Ca 2ϩ , 1 mmol/l Mg 2ϩ , 25 mmol/l HEPES, pH 7.4; Gibco), antibiotics and fungizone as above; 300 IU/ml Collagenase Type IV (Worthington, Freehold, NJ, USA) and 22.5 IU/ml DNase I (Worthington). The dispersion 758 process included trituration every 3 min with decreasing bore-size pipettes, collection of supernatants by centrifugation (20 g for 5 min) at room temperature every 10 min and addition of fresh dispersion solution. The pooled supernatants were centrifuged at 430 g for 10 min. The separated cells were washed twice with the wash buffer and once with the growth medium (Minimal Essential Medium; Gibco) supplemented with 10% (v/v) fetal calf serum, 2 mmol/l Lglutamine, 1 mmol/l sodium pyruvate; antibiotics and fungizone as above. They were then resuspended in adequate volume of growth medium, plated and grown at 37°C in a 5% CO 2 /95% humidified air incubator. Medium was changed every 3 days (Andersen et al., 1993; Zhao et al., 1996) .
Preparation of nuclear extract
To obtain sufficient quantity of nuclear proteins, the cultures were passaged four times. A total of 50 culture dishes (150ϫ15 mm) of cells (~3ϫ10 9 cells) were used per experiment. After change of media , the cells were treated for 6-8 h with phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), (CalbiochemNovobiochem Corporation, La Jolla, CA, USA) at 100 ng/ml, harvested and nuclear extract made by a modified method (Shapiro et al., 1988 ) using a hand-held Dounce homogenizer. The modification included the addition of protease inhibitors: leupeptin and aprotinin, at 2 µg/ml; pepstatin-A (1 µg/ml), and phosphatase inhibitor (β-glycerophosphate) (10 mmol/l) to all buffers except the dialysis buffer which contained only β-glycerophosphate as an addition. Extracts were divided into small volume aliquots, flash-frozen in liquid nitrogen and stored at -70°C till used.
Plasmid constructs
A 312 bp fragment (-164 to ϩ148) was amplified using the polymerase chain reaction (PCR) from a 6 kb EcoRI human Cx43 gene 5Ј-region that was cloned into pGF10 and kindly supplied by Dr G.I.Fishman (Fishman et al., 1991) . The PCR primers contained KpnI and XbaI sites, which were used to insert the 312 bp fragment into a pUC19 polycloning site to create pCx312. The primers were: Sense: 5Ј-GCGCGGTACCGATCCCACTGCTCTTTG-3Ј Antisense: 5Ј-GCGCTCTAGACCTTGGAGGATGAAGTAAAATG-3Ј.
A 171 bp fragment (-164 to ϩ7), was excised from the 312 bp fragment and inserted into KpnI/HindIII sites of pUC19 and is hereafter referred to as pCx171. The sequences of the fragments were confirmed by the dideoxy chain termination method.
In-vitro mutagenesis
Seven independent 10 bp replacement mutants (seriatim linker scan spanning -99 to -30 of the promoter) were made using PCR from pCx312 (Vallette et al., 1989; Vanden Heuvel et al., 1993) . A 10 bp sequence 5Ј-ATCTCGAGAT-3Ј bearing a unique XhoI site was used for each replacement. were also constructed as additional checks for the ∆-99/-90, ∆-79/-70 and ∆-59/-50 mutations. Briefly, the 312 bp fragment was excised from pCx312 and inserted into PGL3 basic vector in the KpnI/BglII cloning site and mutagenesis was performed directly in this vector using transformer site-directed mutagenesis kit (Clontech Labs Inc, Palo Alto, CA, USA) and the following primers:
for ∆-93/-91: 5Ј-CAAAGGGAAAGGCTAAAAGGAGGTAG-GGAG-3Ј, ∆-74/-72: 5Ј-GCTAGAAGAAAGGGACAGGCAAAGGGAAA- 
DNase I footprinting
DNase I footprint assay (Angel et al., 1987) was performed in a 25 µl reaction mixture containing (final concentration); 10 mmol/l HEPES (pH 8.0), 1.6 mmol/l dithiothreitol (DTT), 5 mmol/l MgCl, 0.1 mmol/l EDTA, 25 mmol/l KCl, 1 µg [poly (dI-dC). poly (dIdC)], (Pharmacia), 12% glycerol, 5 µg bovine serum albumin (BSA), nuclear proteins (0.0 to 60 µg) and 1ϫ10 5 cpm (0.1 pmoles) of labelled DNA. After incubation on ice for 60 min, samples were equilibrated for 3 min at room temperature and digested for 1 min. with 0.5-6 µl of DNase I (Worthington) diluted to 6.25 µg/ml in buffer (10 mmol/l HEPES, pH 7.6, and 25 mmol/l CaCl 2 ). The reaction was terminated with 200 µl of stop buffer (10 mmol/l TrisHCl, pH 7.6, 20 mmol/l EDTA, 3 µg/ml sheared calf thymus DNA, 0.2 mg/ml proteinase K and 0.2% sodium dodecyl sulphate), then incubated for 45 min at 37°C. After phenol-chloroform extraction, the DNA was ethanol-precipitated, resuspended in formamide dye mixture (95% formamide, 0.05% Bromophenol Blue and 0.05% Xylene Cyanol FF) and fractionated on 8% polyacrylamide sequencing gel along with a GϩA chemical sequencing reaction lane (Maxam and Gilbert, 1980) and visualized by autoradiography.
Electrophoresis motility shift assay (EMSA)
Standard EMSA were performed with [γ-32P]ATP-labelled doublestranded oligonucleotides. Binding reactions (15 µl) contained 10 mM Tris-HCl (pH 7.6), 50 mmol/l KCl, 5 mmol/l DTT, 0.5 mmol/ l EDTA, 1 mmol/l MgCl 2 and varying amounts of nuclear extract and poly (dI-dC) as indicated in the figure legends. The mixture was incubated on ice for 10 min, then 5.0-7.5ϫ10 4 cpm of label was added and the incubation was continued for 25 min at 25°C. Samples were then fractionated on 4% non-denaturing polyacrylamide gel with 0. -32/-9: 5Ј-TTGAAACTTTTAAAAGCTCTGTGC-3Ј bA-4: 5Ј-TCTTCGCATCCCTCCTCCAGT-3Ј, motif found in chicken adult β-globin gene (Emerson et al., 1985) .
Transient transfections
Human myometrial primary culture cells between second and fourth passages were plated to~50-60% confluence in 60 mm diameter culture dishes. They were transfected with 20 µg total DNA (15.0 µg of test plasmids, 1.0 µg of internal control pCMVlacZ plasmid and 4.0 µg of Salmon sperm DNA) by the calcium phosphate procedure. At 4-6 h post-transfection, the cells were glycerol-shocked for 1 min, washed with phosphate-buffered saline (PBS) and supplemented with fresh medium. Cells were harvested 48 h later, lysed and assayed for luciferase using the Promega Luciferase Assay System (Promega). β-Galactosidase activity was measured by the standard colorimetric method and used for normalizing luciferase activity.
Co-transfection with c-Jun, c-Fos and Sp1 expression plasmids
The following plasmids were used: pCMV Sp1, which over-expresses Sp1, was generously provided by R.Tjian; pCMV c-Jun and pCMV c-Fos, which over-express c-Jun and c-Fos respectively, were gifts from A.Kopland. Wild-type Cx43 (5 µg; 312 bp) in pGL3 basic-luc reporter was mixed with either 1 µg of each expression plasmid or their combinations containing 1 µg of each plasmid (see legend to Figure 7 for details) and 1 µg of pCMVlacZ. The total DNA was adjusted to 20 µg with salmon sperm DNA. Transfections were performed as described above.
Statistical analysis
The transfection assays were performed four times. Samples in each group of experiments were in duplicates or triplicates. All data were expressed as mean Ϯ SE. One-factor analysis of variance (ANOVA) was used to test the overall hypothesis of no group differences, followed by two-sample t-tests for pairwise comparisons where the overall hypothesis was rejected. P Ͻ 0.05 was considered to be statistically significant.
Results
Transcription factor binding sites within the human Cx43 promoter
It has been demonstrated that TPA treatment of primary myometrial cells in culture leads to stimulation of Cx43 promoter . To define the regions within the promoter of the human Cx43 gene capable of interacting with transcription factors in similarly treated cells we carried out DNase I footprinting analysis. The results using a promoter fragment bearing (relative to the start site of transcription) from -164 to ϩ148 ( Figure 1A ) and from -164 to ϩ7 ( Figure  1B ) demonstrated several protected regions separated by sites of enhanced DNase I sensitivity. Protection on the coding (Figure 1 ) and non-coding (data not shown) strands is indicated in Figure 2 . Region 1 extends from -80 to -31 and encompasses a consensus AP1 site (-44 to -36) and a segment (-80 to -45) that envelops other potential protein binding sites summarized in Figure 2 . The promoter sequence (-65 to -48) homologous to the mouse 'activator' element (Chen et al., 1995) is also located in this region. Three other regions considered further only in the discussion include the site of initiation, Region 2 (-5 to ϩ15), Region 3 (ϩ47 to ϩ70) which is coincident with an Ets/NFkB consensus site and Region 4 (ϩ80 to ϩ 100) that spans a TA-rich site (ϩ81 to ϩ96). Note that transcription factor binding was not observed either within the CCTCC/AP2 sequence (-93 to -87) which corresponds to the mouse 'repressor' site (Chen et al., 1995) , or at the AP2 consensus (-134 to -127).
c-Jun binds to the AP1 consensus site of the Cx43 promoter
Previous studies have suggested that Cx43 promoter activation through the proximal AP1 site following TPA treatment of primary myometrial cells relies on the concomitant increase in c-Jun and c-Fos protein concentrations. To test this directly, we performed mobility shift and supershift assays using a double-stranded oligonucleotide that encompassed the AP1 consensus site (-52 to -29) . Incubation of the radiolabelled Cx43 AP1 motif with nuclear extracts derived from TPA-treated primary myometrial cell cultures (Figure 3 A was competed by inclusion of non-labelled self ( Figure 3A , lane 8) or by a commercially available oligonucleotide containing the consensus AP1 binding motif ( Figure 3A , lane 9; Figure 3B , lane 10). Competition was not observed with a mutated AP1 binding motif that does not support AP1 binding ( Figure 3B , lane 11). These data support the notion that this region within the Cx43 promoter is an AP1-binding site. AP1 is a family of dimeric transcription factors comprised of either c-Jun homodimers or heterodimers of certain Jun/ Fos family members. In order to identity the Jun/Fos family members within the band-shifted nucleoprotein complex, we initially performed supershift analysis using a monoclonal c-Jun antibody specific for phosphorylated c-Jun (c-JunP, Figure 3A , lane 4,), and polyclonal antibodies raised against the aminoterminal regions of either the c-Jun (c-Jun, Figure  3A , lane 3) or c-Fos (c-Fos, Figure 3A , lane 5) proteins. In Figure 3A , a supershift for phosphorylated c-Jun was observed (lanes 4 and 7). However, supershifts were not observed with c-Jun (lanes 3 and 6) or c-Fos (lanes 5 and 6) either alone (lanes 3 and 5) or in combination (lane 6). It was surprising that c-Jun antibody had no effect on band mobility since this antibody should have recognized both the phosphorylated and non-phosphorylated forms of c-Jun. Therefore, we repeated these experiments using a polyclonal antibody (pan Jun) that recognizes a highly conserved region of the DNA binding domain of Jun family members c-Jun, Jun B and Jun D. As expected, this antibody disrupted Jun binding when either myometrial ( Figure 3B, lane 3) or HeLa cells ( Figure 3B , lane 7) were used as a protein source. The supershift assay performed with the c-JunP antibody demonstrated that phosphorylated c-Jun was present within the myometrial-derived complex ( Figure 3B , lane 5) but not within the nucleoprotein complex formed using the HeLa cell nuclear extract ( Figure  3B , lane 9). This latter result was not entirely unexpected since the HeLa cell extracts were prepared using buffers that lacked phosphatase inhibitors. In contrast, preincubation of myometrial ( Figure 3B , lane 4) or HeLa cell nuclear extracts (lane 8) with pan Fos (which recognizes the amino terminus of Fos family members c-Fos, Fos B, Fra-1 and Fra-2) prior to addition of the labelled oligonucleotide had no effect on 761 the mobility shift. These data suggest that the AP1 motif within the Cx43 promoter was recognized either by a Jun homodimer or a heterodimer comprised of Jun and either an undefined Fos family member or the CREB/ATF family that often heterodimerize with Jun.
Identification of Sp1 binding sites in Cx43 promoter
We next sought to identify the factor(s) that bind to the rest of Region 1 encompassing from -80 to -45. Based on the extent of DNase I protection, this region probably contains tandem transcription factor binding sites. A portion of this region (-65 and -48 ) is homologous to the mouse 'activator' element (Chen et al., 1995) . This element overlaps a sequence motif (-59 to -48) that resembles the 'CCTCC' elements, reported to bind the ubiquitous transcriptional activator protein Sp1 and found within the promoters of rat growth hormone (Schaufele et al., 1990) , low density lipoprotein receptor promotors (Dawson et al., 1988) and CDC11c promotors (Noti et al., 1996) . The upstream portion of Region 1 (-77 to -69) contains another CCTCC motif. Electrophoretic mobility shift assay was performed using a double-stranded oligonucleotide spanning the Cx43 promoter from -100 to -50 (Figure 4) . We included the DNase I sensitive promoter sequence from (-100 to -81) because the sequence (-93 to -87) corresponds to the mouse 'repressor' element (Chen et al., 1995) . Note also that the sequence from -99 to -89 (5Ј-CCTCCTCCCAG) is homologous to a portion of the CCTCC element within the downstream portion of Region 1 (-56 to -46).
The results in Figure 4 show two major (a and c) and a minor (b) complex formed using extracts from the TPA-treated primary myometrial cell cultures (lane 2). The complexes are competed out at 200-fold excess of unlabelled oligonucleotides for self -100/-50 (lane 3) indicating site specificity. We also performed competition analysis using selected subregions of the -100/-50 segment. All three bands were efficiently competed by addition of an unlabelled oligonucleotide derived from Region 1 containing either the distal CCTCC motif (-83/-65, lanes 11 and 12) or the proximal CCTCC motif and overlapping mouse activator element (-70/-48 lanes 5 and 6). Competition was also demonstrated (data not shown) with a Radiolabelled oligonucleotide -52/-29 was incubated as described in (A) without added protein (lane 1), or with 5 µg of myometrial extract (lanes 2-5), or HeLa extract (lanes 6-11). Polyclonal pan-Jun antibody (Sc-44X) was added to lanes 3 and 7; plyclonal pan Fos (Sc-413X) was added to lanes 4 and 8 and monoclonal antiphosphorylated c-Jun (Sc-822X) was added to lanes 5 and 9. Lanes 10 and 11 contained 100-fold excess AP1 consensus and mutant oligonucleotides respectively. consensus SP1 oligonucleotide and an oligonucleotide that contained the CCTCC motif found within the chicken adult β-globin promoter (Emerson et al., 1985) . Competition was not observed using oligonucleotide (-139/-119) that contained a consensus AP2 site, (lanes 9 and 10) or the non-related Region 4 sequence (ϩ50/ ϩ73, lanes 13, 14) . The -80/-100 oligonucleotide (which encompasses the homologous mouse 'repressor' region and contains an overlapping AP2 consensus and CCTCC-like elements) partially competed for complex formation (lanes 7 and 8). We attribute this to the CCTCC motif within this sequence. These data indicate that all three nucleoprotein complexes contain factors bound at the CC-TCC motifs.
The CCTCC motif has been reported to bind the ubiquitous transcriptional activator protein Sp1 (Dawson et al., 1988; Noti et al., 1996) . To test this prediction we performed supershift analysis using an anti Sp1 antibody ( Figure 5 , lane 6). We conclude from these and other similarly performed experiments (data not shown) that the nucleoprotein complexes a and b contain Sp1. The identity of the protein(s) within complex c remains to be determined. It is possible that this nucleoprotein complex contains the 'activator' protein that appears not to be Sp1 (Chen et al., 1995) . In this regard, recall that all three complexes were effectively competed for by either the -70/-48 or-83/-64 oligonucleotides. These sequences also contain the motif 5Ј-TCC-3Ј identified as the core binding bases for most Ets family of transcription factors (Batchelor et al., 1998; Graves, 1998) . The Ets family of transcription factors comprises more than 20 distinct proteins found in different organisms. Preliminary studies, however, indicated that complex c was unaffected by competition with a consensus oligonucleotide recognized by a subset of Ets family members (lane 7). Additionally, no effect was observed when supershift assays were performed with antibodies that recognize the Ets family members PU1 (lane 3), Ets1/Ets2 (lane 4) and GABPα/ β (lane 5). The identity of the protein(s) within complex c remains unresolved. 
AP1 and Sp1 binding sites are necessary for Cx43 promoter activity
To determine the functional importance of the defined elements on Cx43 promoter activity, we performed transient expression assays using human myometrial primary cell cultures and Cx43 10 bp replacement mutant promoter constructs. The results ( Figure 6A) show that systematic replacement mutations in the region -99 to -60 did not adversely affect promoter activity. However, sequential replacement mutations in the region -59 to -39, resulted in a dramatic reduction in promoter activity. In particular, a five-fold reduction in promoter activity was observed when either the proximal Sp1 (∆-59/-50, lane 4) or AP1 (∆-49/-40 and ∆-39/-30, lanes 5 and 6) sites were mutated. Minimal base substitution has previously demonstrated that the AP1 site is required for maximal minimal promoter activity . Using a similar strategy we constructed a series of 2 or 3 bp replacement mutants directed against core sequences within the 'repressor' (∆-93/-91) distal Sp1 (∆-74/-72) 'activator' (∆-59/-58) and proximal Sp1 (∆-55/-53) binding elements. The levels of expression determined by transient expression analyses ( Figure  6B ) support the conclusion that both the binding sites for AP1 (-44 to -36; Geimonen et al., 1996) , and Sp1 (-56 to -49; this report), are required for maximal human myometrial Cx43 core promoter activity.
Sp1 and c-Jun up-regulate Cx43 transcription
To determine whether Sp1 and c-Jun can enhance Cx43 promoter activity, wild-type Cx43 
Discussion
Increase of myometrial gap junctions prior to and at term or preterm labour has been attributed to differential transcriptional and translational regulation. To understand the transcriptional control, we began systematic studies to identify the cis-elements in the human Cx43 promoter that interact with transcription factors from human myometrium. We used in-vitro DNase I footprinting to define potential regulatory elements within the promoter region (-164 to ϩ148) summarized in Figure 2 . We identified four regions of protection: Region 1 encompassed~50 bp of promoter sequence upstream of the RNA start site; Region 2 includes the start site; Regions 3 and 4 were localized to downstream sequences ( Figure 1A ). We then focused on Region 1 (-80 to -31) which contains an AP1 element (-44 to -36) and a region homologous to the 'activator' region found in the mouse Cx43 promoter (Chen et al., 1995) . We have demonstrated by EMSA/supershift assays that c-Jun binds at the AP1 site (-44 to -36) and that Sp1 binds at tandem sites (-59 to -48 and -77 to -69) . Mutational and transient transfection studies indicated that the AP1 and the proximal Sp1 sites are important for maximal promoter function. Over-expression studies indicated that Sp1 and c-Jun either alone or in combination stimulate transcription.
We were unable to demonstrate c-Fos binding to the AP1 site and over-expression of c-Fos either alone or in combination with c-Jun and or c-Fos slightly inhibited promoter activity. TPA treatment of primary myometrial cells in culture increases Cx43 expression and requires a functional AP1 site . TPA treatment of cells increases their levels of c-Jun and c-Fos proteins. Activation however, was not observed when c-Jun and or c-Fos were over-expressed in the absence of TPA-treatment. Thus it was postulated that TPA functioned by activating c-Jun/c-Fos via phosphorylation. In contrast, we performed similar over-expression experiments in cells not treated with TPA. The results (Figure 7) showed that over-expression of c-Jun stimulates promoter activity while over-expression of c-Fos either alone or in combination with c-Jun is slightly inhibitory. Figure 7 also showed that overexpression of Sp1 either alone or in combination with c-Jun stimulates promoter activity. Over-expression of c-Fos either alone or in combination with c-Jun and or Sp1 always resulted in slightly inhibited transient expression. The inhibitory effect of c-Fos and the inability to detect the Fos family in gel shifts ( Figure 3A ,B) lend support to the notion that the AP1 site is bound by c-Jun homodimers or heterodimers of c-Jun and either unidentified Fos family members or other factors known to interact with c-Jun (such as ATF/CREB).
The Sp1 family of proteins includes Sp1, Sp2, Sp3 and Sp4 which bind to the canonical GC-box, (CCCGCCC; Kadonaga et al., 1986 Kadonaga et al., , 1988 and to the non-canonical CCTCC element found in several gene promoters: rat growth hormone (Schaufele et al., 1990) , low density lipoprotein receptor (Dawson et al., 1988) , HIV-1 LTR CDC11c (Noti et al., 1996) and KDR (Hata et al., 1998) . Our data (Figures 4 and 5 ) strongly indicates that Region 1 contains tandem Sp1 binding sites upstream of the AP1 element. In addition, this region promotes nucleoprotein complex formation (c) of unknown composition. Based on studies of the KDR promoter which contains an Sp1/Sp3 binding element identical to that found within the Cx43 promoter Region 1 -60 to -51 (5Ј-AGCCCCTCCTCC-3Ј), this complex could 764 contain Sp3. This study also determined which residues were important (underline) or critical (bold-faced) for binding.
Our data from promoter mutagenesis and transfection analyses demonstrated that only the proximal Sp1 site (-59 to -48) is functionally important and could correspond to the mouse 'activator' element. The mouse 'activator' was defined using an oligonucleotide (5Ј-TTCTCCTAGCCCCTCCTT-3Ј) that overlaps the human consensus Sp1 -67 to -50 (5Ј-TTCTTCTAGCCCCTCCTC-3Јand contains the critical Sp1 binding motif (bold). Mutations in the important region of the mouse activator (GC→TT, AGCCCCTCCTT) had a modest effect on activator protein binding. Paradoxically, this mutant also abolished promoter activity in transient expression studies. In contrast, our studies indicate that an identical mutation had essentially no effect on promoter activity. These discrepancies could be due to differences in promoter constructs used in the assays. The mouse study used a 5Ј-deletion construct that removed the distal Sp1 binding motif whereas our strategy was to perform mutational analysis within the context of the entire minimal promoter sequence. Thus, it is possible that the GC→TT mutation in the human sequence may be recompensed by the distal Sp1 binding site which is absent in the mouse deletion construct (Chen et al., 1995) .
The mouse promoter also contains a 'repressor' element corresponding to a GC-box type (CCCGCC, -96 to-91) Sp1 site (Chen et al., 1995) . These studies demonstrated that mutation ∆-96/-94 (CCC→TTT) in the 'repressor' abolished both protein binding and repressive ability. However susceptibility of this region in the human promoter to DNase I digestion in our foot print experiment ( Figure 1A ) and the minimal effect of identical mutational analysis on promoter activity ( Figure 6A ,B) strongly suggest that this region of the Cx43 promoter has diverged from the mouse promoter. Lack of repressor function is consistent with the A→C transversion within this region of the human CX43 promoter (CCCAGCC) which would be expected to abolish binding of Sp family members.
High levels of transcriptional activation by Sp1 require multiple Sp1 binding sites close to the transcription start site , although a single binding site appears to be sufficient for a promoter to be stimulated by Sp1 (Kadonaga et al., 1987) . Cx43 promoter appears to contain tandem Sp1 binding sites (Figure 2 ). Our data however indicate that only the proximal Sp1 and the adjacent AP1 sites are required for maximal promoter activity. Sp1 recognition sequences are often found near binding sites for other transcription factors, CTF/NF-1 (Jones et al., 1985) and AP1 (Lee et al., 1987a; Angel et al., 1987) . Moreover, synergy has been observed for adjacent AP1 and Sp1 sites in other promoters (Lee et al., 1987b; Noti et al., 1996; Ye et al., 1996) . It is not clear how AP1 and Sp1 interact to regulate Cx43 promoter activity, but Sp1 has been shown to interact physically with a component, dTAF II 110 at the transcription factor IID (TFIID) that binds to the TATA-box element (Gill et al., 1994) . Cx43 promoter has a properly positioned TATA-like element (-25 to -19) that is not protected from DNase I digestion, yet transcription, initiates accurately at the start site (Yu et al., 1994; DeLeon et al., 1994; Chen et al., 1995; Geimonen et al., 1996) . Sp1 interaction with dTAF II 110 could stimulate transcription by facilitating TFIID recruitment into the preinitiation complex. However, other elements might be used in establishing the level of promoter activity.
Such other elements within the context of this study are the down-stream protected regions (2-4) which include the transcription initiation site, an Ets/NF-kB site and a TArich segment. The initiation site has the ascribed function of binding the RNA polymeraseII and other factor(s) such as the initiator factor (Zenzie-Gregory et al., 1992) required for accurate transcription initiation. The NF-kB family of proteins is induced as defensive response to stress, injury, viral as well as bacterial pathogens (Siebenlist et al., 1994) . It is up-regulated by tumour necrosis factor (TNF)-α, lipopolysaccharides, interleukins and TPA, and itself regulates a number of stress as well as defensive genes. Labour is a stress process for both mother and fetus, and may require the intervention of NF-kB activity. The roles that these elements may play in uterine Cx43 transcriptional regulation are, as yet, unknown.
In summary, our studies are the first to demonstrate by in-vitro DNase I foot printing potential regulatory protein binding sites in the region -164 to ϩ148 of the human myometrial Cx43 promoter. We show that c-Jun and Sp1 proteins bind to the promoter and independently up-regulate its activity but are both required for maximal promoter function. These data suggest that Sp1 and c-Jun may positively regulate transcription of myometrial Cx43 during the initiation of labour.
